These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26448572)

  • 1. Increased Serum LIGHT Levels Correlate with Disease Progression and Severity of Interstitial Pneumonia in Patients with Dermatomyositis: A Case Control Study.
    Kotani T; Takeuchi T; Ishida T; Masutani R; Isoda K; Hata K; Yoshida S; Makino S; Hanafusa T
    PLoS One; 2015; 10(10):e0140117. PubMed ID: 26448572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of increased serum leucine-rich α2-glycoprotein levels with disease prognosis, progression, and activity of interstitial pneumonia in patients with dermatomyositis: A retrospective study.
    Ishida T; Kotani T; Serada S; Fujimoto M; Takeuchi T; Makino S; Naka T
    PLoS One; 2020; 15(6):e0234090. PubMed ID: 32479560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study.
    Oda K; Kotani T; Takeuchi T; Ishida T; Shoda T; Isoda K; Yoshida S; Nishimura Y; Makino S
    Sci Rep; 2017 May; 7(1):1635. PubMed ID: 28487565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis.
    Ishikawa Y; Iwata S; Hanami K; Nawata A; Zhang M; Yamagata K; Hirata S; Sakata K; Todoroki Y; Nakano K; Nakayamada S; Satoh M; Tanaka Y
    Arthritis Res Ther; 2018 Oct; 20(1):240. PubMed ID: 30367666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease.
    Lou Y; Zheng Y; Fan B; Zhang L; Zhu F; Wang X; Chen Z; Tan X; Wei Q
    BMC Pulm Med; 2020 Jul; 20(1):196. PubMed ID: 32680574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis.
    Chen M; Quan C; Diao L; Xue F; Xue K; Wang B; Li X; Zhu X; Zheng J; Cao H
    Br J Dermatol; 2018 Dec; 179(6):1334-1341. PubMed ID: 30101523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease.
    Shu X; Peng Q; Lu X; Wang G
    PLoS One; 2016; 11(8):e0161436. PubMed ID: 27537498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease.
    Hozumi H; Fujisawa T; Enomoto N; Nakashima R; Enomoto Y; Suzuki Y; Kono M; Karayama M; Furuhashi K; Murakami A; Inui N; Nakamura Y; Mimori T; Suda T
    J Rheumatol; 2017 Sep; 44(9):1394-1401. PubMed ID: 28711881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
    Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
    Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis.
    Arai S; Kurasawa K; Maezawa R; Owada T; Okada H; Fukuda T
    Mod Rheumatol; 2013 Sep; 23(5):872-83. PubMed ID: 22983659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients.
    Fujiki Y; Kotani T; Isoda K; Ishida T; Shoda T; Yoshida S; Takeuchi T; Makino S
    Mod Rheumatol; 2018 Jan; 28(1):133-140. PubMed ID: 28490218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Surfactant proteins-A and D as important serum markers for interstitial lung disease in patients with polymyositis or dermatomyositis].
    Chen F; Shu XM; Wang DX; Xie Y; Wang GC
    Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2182-5. PubMed ID: 23158422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.
    Gono T; Kaneko H; Kawaguchi Y; Hanaoka M; Kataoka S; Kuwana M; Takagi K; Ichida H; Katsumata Y; Ota Y; Kawasumi H; Yamanaka H
    Rheumatology (Oxford); 2014 Dec; 53(12):2196-203. PubMed ID: 24970922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease.
    Nara M; Komatsuda A; Omokawa A; Togashi M; Okuyama S; Sawada K; Wakui H
    Mod Rheumatol; 2014 Jul; 24(4):633-6. PubMed ID: 24252021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum progranulin levels are elevated in dermatomyositis patients with acute interstitial lung disease, predicting prognosis.
    Tanaka A; Tsukamoto H; Mitoma H; Kiyohara C; Ueda N; Ayano M; Ohta S; Kimoto Y; Akahoshi M; Arinobu Y; Niiro H; Tada Y; Horiuchi T; Akashi K
    Arthritis Res Ther; 2015 Feb; 17(1):27. PubMed ID: 25888887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis.
    Peng QL; Zhang YM; Liang L; Liu X; Ye LF; Yang HB; Zhang L; Shu XM; Lu X; Wang GC
    Clin Exp Immunol; 2020 Mar; 199(3):314-325. PubMed ID: 31797350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Levels of Soluble CD206 Associated with Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis.
    Shen YW; Zhang YM; Huang ZG; Wang GC; Peng QL
    Mediators Inflamm; 2020; 2020():7948095. PubMed ID: 33192174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of cyclosporine A on rapidly progressive interstitial pneumonia in dermatomyositis.
    Miyake S; Ohtani Y; Sawada M; Inase N; Miyazaki Y; Takano S; Miyasaka N; Yoshizawa Y
    Sarcoidosis Vasc Diffuse Lung Dis; 2002 Jun; 19(2):128-33. PubMed ID: 12102608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-treatment ferritin level and alveolar-arterial oxygen gradient can predict mortality rate due to acute/subacute interstitial pneumonia in dermatomyositis treated by cyclosporine a/glucocorticosteroid combination therapy: a case control study [corrected].
    Isoda K; Takeuchi T; Kotani T; Hata K; Shoda T; Ishida T; Yoshida S; Kimura Y; Makino S; Hanafusa T
    PLoS One; 2014; 9(2):e89610. PubMed ID: 24586910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble CXCL16 is a prognostic biomarker associated with rapidly progressive interstitial lung disease complicated with dermatomyositis.
    Li C; Han Y; Li X; Zhang H; Yao Z; Zhou J; Mu R; Zhao J
    Semin Arthritis Rheum; 2024 Aug; 67():152483. PubMed ID: 38843569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.